$AMGN Company News Dow industrials venture to
Post# of 88933
Posted On: 10/08/2014 12:54:24 PM
$AMGN Company News
Dow industrials venture to uncharted territory 9:53 a.m. Sept. 17, 2014 - Michael Ashbaugh
Nasdaq breaks out, reaches less-charted territory 12:05 p.m. Aug. 19, 2014 - Michael Ashbaugh
Nasdaq breaks out, reaches less-charted territory 11:56 a.m. Aug. 19, 2014 - Michael Ashbaugh
Nasdaq breaks out, reaches less-charted territory 11:44 a.m. Aug. 19, 2014 - Michael Ashbaugh
Berkshire Hathaway tops $200,000; Cisco drops on results 12:19 p.m. Aug. 14, 2014 - Angela Johnson
Cisco volatile after hours in wake of earnings 5:03 p.m. Aug. 13, 2014 - Sue Chang
Amgen recalls syringes of anemia drug Aranesp 4:55 p.m. Aug. 13, 2014 - Russ Britt
CORRECT: Amgen shares fall after-hours on disappointing trial data 4:34 p.m. Aug. 13, 2014 - Tomi Kilgore
U.S. stocks rally; Dow snaps 4-session losing streak 4:14 p.m. Aug. 4, 2014 - Barbara Kollmeyer
Mobileye rises for second day; Michael Kors falls 1:23 p.m. Aug. 4, 2014 - Angela Johnson
Amgen shares rally 2.7% to top S&P 500 9:30 a.m. Aug. 4, 2014 - Sue Chang
Amgen reports successful late-stage trial of cancer treatment 8:34 a.m. Aug. 4, 2014 - Joshua Jamerson
Amgen reports positive trial of multiple myeloma treatment 7:49 a.m. Aug. 4, 2014 - Ciara Linnane
Tesla Shares Weaken in After Hours 8:13 p.m. July 31, 2014 - MarketWatch
Small health companies see large gains on a big earnings day 5:34 p.m. July 30, 2014 - blogs.marketwatch.com
Twitter, U.S. Steel soar; Buffalo Wild Wings are burned 4:26 p.m. July 30, 2014 - MarketWatch
Edwards, Hospira rise as health-care companies see strong earnings 1:08 p.m. July 30, 2014 - blogs.marketwatch.com
Amgen shares hit record on cost-cutting plans 10:50 a.m. July 30, 2014 - blogs.marketwatch.com
Twitter shines; Fed statement and GDP due today 4:38 a.m. July 30, 2014 - MarketWatch
Amgen plans to cut up to 2,900 jobs 9:04 p.m. July 29, 2014 - MarketWatch.com
Amgen's Data on Evolocumab Published in The Lancet - Analyst Blog 11:20 a.m. Today - Zacks.com
Phase 3 successful for Amgen's adalimumab biosimilar 9:47 a.m. Today - Seeking Alpha
Dollar Daze 4:11 p.m. Oct. 7, 2014 - Barrons.com
Comparing America's 2 Largest Biotechnology Companies 1:57 p.m. Oct. 7, 2014 - Seeking Alpha
Kinder Morgan Energy Partners Edges Berkshire Hathaway For 'Best Value Bond Trade' 2:38 a.m. Oct. 7, 2014 - Seeking Alpha
Some Old Stocks Still Have Young Legs 5:47 p.m. Oct. 6, 2014 - Investors Business Daily
Ligand Earns Milestone Payment on EU Approval of Noxafil - Analyst Blog 1:00 p.m. Oct. 2, 2014 - Zacks.com
Stock Market News for October 02, 2014 - Market News 10:10 a.m. Oct. 2, 2014 - Zacks.com
Evolocumab successful in two Phase 3 studies 8:15 a.m. Oct. 2, 2014 - Seeking Alpha
Amgen, Inc. Showing Strong Performance Despite Low Beta 11:06 a.m. Sept. 30, 2014 - benzinga.com
Celgene Has A Very Bright Future Ahead 4:26 p.m. Sept. 29, 2014 - Seeking Alpha
AMGN, ACT And GILD, Pushing Drugs Industry Downward 1:03 p.m. Sept. 29, 2014 - TheStreet.com
3 Likely Biotech Buyout Candidates 7:48 a.m. Sept. 29, 2014 - 247WallSt.com
'Tax Inversions' Are Tip Of An Iceberg That Already Cost The U.S. Treasury Hundreds Of Billions 2:50 a.m. Sept. 28, 2014 - Seeking Alpha
Celldex (CLDX) Up on Pilot Study Initiation on CDX-301 - Analyst Blog 5:20 p.m. Sept. 26, 2014 - Zacks.com
'Fast Money' Recap: How to Trade After the Market's Drop 5:00 a.m. Sept. 26, 2014 - TheStreet.com
Seattle Genetics' Adcetris Positive in Durability Analysis - Analyst Blog 6:27 p.m. Sept. 25, 2014 - Zacks.com
BioMarin (BMRN) Faces Threat of Genericization for Kuvan - Analyst Blog 6:24 p.m. Sept. 25, 2014 - Zacks.com
Acorda Skyrockets on $525M Civitas Therapeutics Deal - Analyst Blog 5:47 p.m. Sept. 25, 2014 - Zacks.com
Gilead Scores with TAF-based HIV Regimen, Shares Up - Analyst Blog 5:20 p.m. Sept. 25, 2014 - Zacks.com
Amgen Announces Positive Top-Line Results From Phase 3 Study Evaluating The Efficacy And Safety Of Biosimilar Candidate ABP 501 Compared With Adalimumab In Patients With Moderate-To-Severe Plaque Psoriasis 9:15 a.m. Today - PR Newswire - PRF
Global Biosimilar Market Outlook 2018 8:09 p.m. Oct. 1, 2014 - PR Newswire - PRF
The Lancet Publishes Two Phase 3 Studies Showing Cholesterol-Lowering Medication Evolocumab Significantly Reduced LDL Cholesterol In Patients With Serious Genetic Disorders That Cause High Cholesterol 7:01 p.m. Oct. 1, 2014 - PR Newswire - PRF
Earnings Release Schedules, Data Presentation, Regulatory Approvals, and Strategic Collaboration - Research Reports on Covidien, Biogen, Amgen, Agios and Baxter 8:55 a.m. Oct. 1, 2014 - PR Newswire - PRF
Bococizumab (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023 3:55 p.m. Sept. 29, 2014 - PR Newswire - PRF
Amgen to Host Summary Webcast of Kyprolis® (carfilzomib) for Injection Data Presented at The European Society for Medical Oncology (ESMO) 2014 Congress 5:02 p.m. Sept. 24, 2014 - PR Newswire - PRF
Q Therapeutics Expands Board of Directors With Appointment of Dr. Hunter Jackson as Independent Member 4:22 p.m. Sept. 23, 2014 - Marketwire
Regulatory Approval, Presentation of Data, Appointment, Clinical Study Results, and Increase in Quarterly Dividend - Research Reports on Johnson & Johnson, Merck, Medtronic, Amgen and Covidien 9:05 a.m. Sept. 23, 2014 - PR Newswire - PRF
Amgen Submits Biologics License Application for Investigational BiTE® Immunotherapy Blinatumomab 9:00 a.m. Sept. 22, 2014 - PR Newswire - PRF
New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 4:00 p.m. Sept. 15, 2014 - PR Newswire - PRF
Event Schedules, Survey Findings, Regulatory Filings, and Market Activity - Research Reports on Amgen, Biogen Idec, Salix, Covidien and Shire 8:50 a.m. Sept. 15, 2014 - PR Newswire - PRF
Amgen Presents Analyses Of Phase 3 Ivabradine Data For The Treatment Of Chronic Heart Failure 9:00 p.m. Sept. 14, 2014 - PR Newswire - PRF
Reporting Bias in Clinical Trials: What's the current status? 10:30 a.m. Sept. 10, 2014 - PR Newswire - PRF
Amgen Announces 23 Abstracts To Be Presented At The American Society for Bone and Mineral Research 2014 Annual Meeting 9:15 a.m. Sept. 10, 2014 - PR Newswire - PRF
Critical Alerts For Alcoa, Twitter, General Mills, SunEdison and Amgen Released By InvestorsObserver 9:31 a.m. Sept. 9, 2014 - PR Newswire - PRF
Zenith Epigenetics Strengthens its Management Team with Key Appointments 5:34 p.m. Sept. 8, 2014 - PR Newswire - PRF
Fitch Affirms Amgen's IDR at 'BBB'; Outlook Remains Negative 3:13 p.m. Sept. 8, 2014 - BusinessWire - BZX
The Psoriatic Arthritis Market Will Reach More than $3.5 Billion in 2023, Owing to Continued Uptake of Biologics and Penetration of Premium-Priced Orals 10:00 a.m. Sept. 8, 2014 - PR Newswire - PRF
Amgen To Present At The Morgan Stanley Global Healthcare Conference 4:04 p.m. Sept. 5, 2014 - PR Newswire - PRF
Upcoming Presentations, Technical Update, Study Results, and Marketing Authorization Application - Research Reports on Novartis, InterMune, Johnson & Johnson, Amgen and Merck 9:00 a.m. Sept. 5, 2014 - PR Newswire - PRF
Dow industrials venture to uncharted territory 9:53 a.m. Sept. 17, 2014 - Michael Ashbaugh
Nasdaq breaks out, reaches less-charted territory 12:05 p.m. Aug. 19, 2014 - Michael Ashbaugh
Nasdaq breaks out, reaches less-charted territory 11:56 a.m. Aug. 19, 2014 - Michael Ashbaugh
Nasdaq breaks out, reaches less-charted territory 11:44 a.m. Aug. 19, 2014 - Michael Ashbaugh
Berkshire Hathaway tops $200,000; Cisco drops on results 12:19 p.m. Aug. 14, 2014 - Angela Johnson
Cisco volatile after hours in wake of earnings 5:03 p.m. Aug. 13, 2014 - Sue Chang
Amgen recalls syringes of anemia drug Aranesp 4:55 p.m. Aug. 13, 2014 - Russ Britt
CORRECT: Amgen shares fall after-hours on disappointing trial data 4:34 p.m. Aug. 13, 2014 - Tomi Kilgore
U.S. stocks rally; Dow snaps 4-session losing streak 4:14 p.m. Aug. 4, 2014 - Barbara Kollmeyer
Mobileye rises for second day; Michael Kors falls 1:23 p.m. Aug. 4, 2014 - Angela Johnson
Amgen shares rally 2.7% to top S&P 500 9:30 a.m. Aug. 4, 2014 - Sue Chang
Amgen reports successful late-stage trial of cancer treatment 8:34 a.m. Aug. 4, 2014 - Joshua Jamerson
Amgen reports positive trial of multiple myeloma treatment 7:49 a.m. Aug. 4, 2014 - Ciara Linnane
Tesla Shares Weaken in After Hours 8:13 p.m. July 31, 2014 - MarketWatch
Small health companies see large gains on a big earnings day 5:34 p.m. July 30, 2014 - blogs.marketwatch.com
Twitter, U.S. Steel soar; Buffalo Wild Wings are burned 4:26 p.m. July 30, 2014 - MarketWatch
Edwards, Hospira rise as health-care companies see strong earnings 1:08 p.m. July 30, 2014 - blogs.marketwatch.com
Amgen shares hit record on cost-cutting plans 10:50 a.m. July 30, 2014 - blogs.marketwatch.com
Twitter shines; Fed statement and GDP due today 4:38 a.m. July 30, 2014 - MarketWatch
Amgen plans to cut up to 2,900 jobs 9:04 p.m. July 29, 2014 - MarketWatch.com
Amgen's Data on Evolocumab Published in The Lancet - Analyst Blog 11:20 a.m. Today - Zacks.com
Phase 3 successful for Amgen's adalimumab biosimilar 9:47 a.m. Today - Seeking Alpha
Dollar Daze 4:11 p.m. Oct. 7, 2014 - Barrons.com
Comparing America's 2 Largest Biotechnology Companies 1:57 p.m. Oct. 7, 2014 - Seeking Alpha
Kinder Morgan Energy Partners Edges Berkshire Hathaway For 'Best Value Bond Trade' 2:38 a.m. Oct. 7, 2014 - Seeking Alpha
Some Old Stocks Still Have Young Legs 5:47 p.m. Oct. 6, 2014 - Investors Business Daily
Ligand Earns Milestone Payment on EU Approval of Noxafil - Analyst Blog 1:00 p.m. Oct. 2, 2014 - Zacks.com
Stock Market News for October 02, 2014 - Market News 10:10 a.m. Oct. 2, 2014 - Zacks.com
Evolocumab successful in two Phase 3 studies 8:15 a.m. Oct. 2, 2014 - Seeking Alpha
Amgen, Inc. Showing Strong Performance Despite Low Beta 11:06 a.m. Sept. 30, 2014 - benzinga.com
Celgene Has A Very Bright Future Ahead 4:26 p.m. Sept. 29, 2014 - Seeking Alpha
AMGN, ACT And GILD, Pushing Drugs Industry Downward 1:03 p.m. Sept. 29, 2014 - TheStreet.com
3 Likely Biotech Buyout Candidates 7:48 a.m. Sept. 29, 2014 - 247WallSt.com
'Tax Inversions' Are Tip Of An Iceberg That Already Cost The U.S. Treasury Hundreds Of Billions 2:50 a.m. Sept. 28, 2014 - Seeking Alpha
Celldex (CLDX) Up on Pilot Study Initiation on CDX-301 - Analyst Blog 5:20 p.m. Sept. 26, 2014 - Zacks.com
'Fast Money' Recap: How to Trade After the Market's Drop 5:00 a.m. Sept. 26, 2014 - TheStreet.com
Seattle Genetics' Adcetris Positive in Durability Analysis - Analyst Blog 6:27 p.m. Sept. 25, 2014 - Zacks.com
BioMarin (BMRN) Faces Threat of Genericization for Kuvan - Analyst Blog 6:24 p.m. Sept. 25, 2014 - Zacks.com
Acorda Skyrockets on $525M Civitas Therapeutics Deal - Analyst Blog 5:47 p.m. Sept. 25, 2014 - Zacks.com
Gilead Scores with TAF-based HIV Regimen, Shares Up - Analyst Blog 5:20 p.m. Sept. 25, 2014 - Zacks.com
Amgen Announces Positive Top-Line Results From Phase 3 Study Evaluating The Efficacy And Safety Of Biosimilar Candidate ABP 501 Compared With Adalimumab In Patients With Moderate-To-Severe Plaque Psoriasis 9:15 a.m. Today - PR Newswire - PRF
Global Biosimilar Market Outlook 2018 8:09 p.m. Oct. 1, 2014 - PR Newswire - PRF
The Lancet Publishes Two Phase 3 Studies Showing Cholesterol-Lowering Medication Evolocumab Significantly Reduced LDL Cholesterol In Patients With Serious Genetic Disorders That Cause High Cholesterol 7:01 p.m. Oct. 1, 2014 - PR Newswire - PRF
Earnings Release Schedules, Data Presentation, Regulatory Approvals, and Strategic Collaboration - Research Reports on Covidien, Biogen, Amgen, Agios and Baxter 8:55 a.m. Oct. 1, 2014 - PR Newswire - PRF
Bococizumab (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023 3:55 p.m. Sept. 29, 2014 - PR Newswire - PRF
Amgen to Host Summary Webcast of Kyprolis® (carfilzomib) for Injection Data Presented at The European Society for Medical Oncology (ESMO) 2014 Congress 5:02 p.m. Sept. 24, 2014 - PR Newswire - PRF
Q Therapeutics Expands Board of Directors With Appointment of Dr. Hunter Jackson as Independent Member 4:22 p.m. Sept. 23, 2014 - Marketwire
Regulatory Approval, Presentation of Data, Appointment, Clinical Study Results, and Increase in Quarterly Dividend - Research Reports on Johnson & Johnson, Merck, Medtronic, Amgen and Covidien 9:05 a.m. Sept. 23, 2014 - PR Newswire - PRF
Amgen Submits Biologics License Application for Investigational BiTE® Immunotherapy Blinatumomab 9:00 a.m. Sept. 22, 2014 - PR Newswire - PRF
New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 4:00 p.m. Sept. 15, 2014 - PR Newswire - PRF
Event Schedules, Survey Findings, Regulatory Filings, and Market Activity - Research Reports on Amgen, Biogen Idec, Salix, Covidien and Shire 8:50 a.m. Sept. 15, 2014 - PR Newswire - PRF
Amgen Presents Analyses Of Phase 3 Ivabradine Data For The Treatment Of Chronic Heart Failure 9:00 p.m. Sept. 14, 2014 - PR Newswire - PRF
Reporting Bias in Clinical Trials: What's the current status? 10:30 a.m. Sept. 10, 2014 - PR Newswire - PRF
Amgen Announces 23 Abstracts To Be Presented At The American Society for Bone and Mineral Research 2014 Annual Meeting 9:15 a.m. Sept. 10, 2014 - PR Newswire - PRF
Critical Alerts For Alcoa, Twitter, General Mills, SunEdison and Amgen Released By InvestorsObserver 9:31 a.m. Sept. 9, 2014 - PR Newswire - PRF
Zenith Epigenetics Strengthens its Management Team with Key Appointments 5:34 p.m. Sept. 8, 2014 - PR Newswire - PRF
Fitch Affirms Amgen's IDR at 'BBB'; Outlook Remains Negative 3:13 p.m. Sept. 8, 2014 - BusinessWire - BZX
The Psoriatic Arthritis Market Will Reach More than $3.5 Billion in 2023, Owing to Continued Uptake of Biologics and Penetration of Premium-Priced Orals 10:00 a.m. Sept. 8, 2014 - PR Newswire - PRF
Amgen To Present At The Morgan Stanley Global Healthcare Conference 4:04 p.m. Sept. 5, 2014 - PR Newswire - PRF
Upcoming Presentations, Technical Update, Study Results, and Marketing Authorization Application - Research Reports on Novartis, InterMune, Johnson & Johnson, Amgen and Merck 9:00 a.m. Sept. 5, 2014 - PR Newswire - PRF
(0)
(0)Scroll down for more posts ▼